- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Managed Healthcare Executive® State of Industry Survey: More Consolidation of Providers in 2022
Forty percent of the respondents to our annual State of the Industry survey expect vertical integration of providers to increase this year.
Scratch beneath the surface of almost any recent trend in healthcare and you’ll find that it is not as new as it might first appear.
But there is really nothing new about consolidation in healthcare. Hospitals have been combining into larger, market-dominating systems for decades. According to a 2020 Medpac report, 90% of hospital markets met Federal Trade Commission definitions for “highly concentrated” in 2017 and there are no indications of the trend reversing since then.
The same is true of the payer side of the street. The Medpac report says 21 of 51 regions (the states plus District of Columbia) had group insurance that were super-concentrated.
Even if consolidation isn’t news, it ranked among the top concerns of the 100 respondents to our annual State of the Industry survey. In fact, it was the top issue when we asked respondents to rank issues in order of importance.
Related: Managed Healthcare Executive® State of the Industry Survey, A Look Ahead , First Installment
We asked also asked which consolidation trend is most likely to accelerate in 2022. Vertical integration of providers (40%) and horizontal integration of providers (24%) garnered many more responses than vertical integration of payers (13%) and horizontal integration of payers (12%).
The Biden administration has said it is going to increase antitrust scrutiny of consolidation in all aspects of the economy, including healthcare. A solid majority (59%) of the respondents to our survey said they favored the administration using antitrust law to slow down or block consolidation among providers.
Most Real-World Studies Report Positive Outcomes of Rituximab Use in Multiple Sclerosis
May 8th 2024Although several clinical trials have confirmed the safety and efficacy of rituximab in oncology and autoimmune disease, and even as off-label use in MS, real-world evidence is still necessary to help guide clinicians and managed care professionals in their treatment and coverage decision-making.
Read More
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
